Considering that the acetylation level of the MRPL12 K163 site is significantly lower in ccRCC tissues compared to adjacent normal tissues, it is likely that the reduced SIRT5-mediated acetylation of the MRPL12 K163 site in ccRCC has little effect on tumour progression, but rather by other regulatory mechanisms. The gene discussed is SIRT5; the disease is nonpapillary renal cell carcinoma.